Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Piotr LewczukDepartment of Neurodegeneration Diagnostics, Medical University of Białystok, and Department of Biochemical Diagnostics, University Hospital of Białystok, Białystok, Poland;Peter RiedererCenter of Mental Health, Clinic and Policlinic of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Würzburg, Germany;Sid E. O’BryantInstitute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA;Marcel M. VerbeekDepartment of Laboratory Medicine, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer center, Nijmegen, The Netherlands;Bruno DuboisInstitut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Salpêtrièrie Hospital, INSERM UMR-S 975 (ICM), Paris 6 University, Paris, France;Pieter Jelle VisserDepartment of Neurology, Alzheimer Centre, Amsterdam Neuroscience VU University Medical Centre, Amsterdam, The Netherlands;K. A. JellingerSebastiaan EngelborghsDepartment of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium;Alfredo Ramı́rezDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany;Lucilla ParnettiSection of Neurology, Center for Memory Disturbances, Lab of Clinical Neurochemistry, University of Perugia, Perugia, Italy;Clifford R. JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA;Charlotte E. TeunissenNeurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center Amsterdam, Amsterdam, The Netherlands;Harald HampelSorbonne UniversitéAlberto LleóCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Spain;Frank JessenDepartment of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany;Lidia GlodzikCenter for Brain Health, Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA;Mony J. de LeonCenter for Brain Health, Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA;Anne M. FaganDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA;José Luís MolinuevoAlzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;Willemijn J. JansenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, The Netherlands;Bengt WinbladKarolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden;Leslie M. ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;Ulf AndréassonClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden;Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany;Brit MollenhauerParacelsus-Elena-Klinik, Kassel and University Medical Center Göttingen, Department of Neurology, Göttingen, Germany;Jens WiltfangDepartment of Psychiatry & Psychotherapy, University of Göttingen, Göttingen, Germany;Martin R. TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK;Inga ZerrClinical Dementia Centre, Department of Neurology, University Medical School, Göttingen, Germany;Ron HandelsDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, The Netherlands;Alexander G. ThompsonNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK;Gunilla JohanssonKarolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden;Natalia ErmannDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany;John Q. TrojanowskiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;Ilker KaracaDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany;Holger WagnerDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany;Patrick OecklDepartment of Neurology, University of Ulm, Ulm, Germany;Linda van Waalwijk van DoornDepartment of Laboratory Medicine, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer center, Nijmegen, The Netherlands;Maria BjerkeReference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium;Dimitrios KapogiannisLaboratory of Neurosciences, National Institute on Aging/National Institutes of Health (NIA/NIH), Baltimore, MD, USA;H. Bea KuiperijDepartment of Laboratory Medicine, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer center, Nijmegen, The Netherlands;Lucia FarottiSection of Neurology, Center for Memory Disturbances, Lab of Clinical Neurochemistry, University of Perugia, Perugia, Italy;Yi LiCenter for Brain Health, Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA;Brian A. GordonDepartment of Radiology, Washington University School of Medicine, Saint Louis, MO, USA;Stéphane EpelbaumInstitut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Salpêtrièrie Hospital, INSERM UMR-S 975 (ICM), Paris 6 University, Paris, France;Stephanie J. B. VosDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, The Netherlands;Catharina J.M. KlijnDepartment of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Nijmegen, The Netherlands;William E. Van NostrandDepartment of Neurosurgery, HSC T-12/086, Stony Brook University, New York, NY, USA;Carolina MinguillónBarcelonabeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;Matthias SchmitzClinical Dementia Centre, Department of Neurology, University Medical School, Göttingen, Germany;Carla GalloDepartamento de Ciencias Celulares y Moleculares/Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru;Andrea Lopez MatoChair of Psychoneuroimmunoendocrinology, Maimonides University, Buenos Aires, Argentina;Florence ThibautDepartment of Psychiatry, University Hospital Cochin-Site Tarnier 89 rue d’Assas, INSERM 894, Faculty of Medicine Paris Descartes, Paris, France;Simone ListaAXA Research Fund & UPMC Chair, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l’hôpital, Paris, France;Daniel AlcoleaCentro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED, Spain;Henrik ZetterbergClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden;Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden;Johannes KornhuberDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany;on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut
2017en
ABI
Annotatsiya
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
3 ta iqtibos0 ta foydalanilgan manba